A circulating ligand for galectin-3 is a haptoglobin-related glycoprotein elevated in individuals with colon cancer1 1Investigators of the Great Lakes-New England Clinical and Epidemiology Center of the Early Detection Research Network are Dean Brenner, Daniel Normalle, and Kim Turgeon (University of Michigan), Sapna Syngal (Dana Farber Cancer Institute), Robert S. Bresalier (University of Texas M.D. Anderson Cancer Center), John Barron (Dartmouth/Hitchcock Medical Center), and Norman Marcon (University of Toronto).

2004 ◽  
Vol 127 (3) ◽  
pp. 741-748 ◽  
Author(s):  
Robert S. Bresalier ◽  
James C. Byrd ◽  
David Tessler ◽  
Joseph Lebel ◽  
John Koomen ◽  
...  
Keyword(s):  
New England ◽  
Medical Center ◽  
Research Network ◽  
Cancer Center ◽  
University Of Michigan ◽  
University Of Texas ◽  
University Of Toronto ◽  
Dana Farber Cancer Institute ◽  
Galectin 3 ◽  
Dartmouth Hitchcock Medical

Program development of a preceptor bootcamp for operational pharmacy preceptors

2020 ◽  
Vol 77 (Supplement_1) ◽  
pp. S2-S7
Author(s):  
Devlin V Smith ◽  
Stefani Gautreaux ◽  
Alison M Gulbis ◽  
Jeffrey J Bruno ◽  
Kevin Garey ◽  
...  
Keyword(s):  
Survey Methodology ◽  
Medical Center ◽  
Academic Medical Center ◽  
Cancer Center ◽  
University Of Texas ◽  
Qualitative Feedback ◽  
Md Anderson ◽  
The University ◽  
Functional Areas ◽  
The Impact

Abstract Purpose To describe the development, design, and implementation of a pilot preceptor development bootcamp and feedback related to its feasibility and impact on operational pharmacy preceptors. Summary The University of Texas MD Anderson Cancer Center designed and implemented a pilot preceptor development bootcamp for operational staff pharmacists serving as residency preceptors for longitudinal weekend staffing experiences. A systematic, multipronged approach was taken to identify preceptor development gaps and design a full-day bootcamp curriculum. The resultant curriculum was comprised of content in major functional areas including using the 4 preceptor roles, documenting performance, giving and receiving feedback, and dealing with difficult situations or learners. The impact of the pilot preceptor development bootcamp was assessed using survey methodology and qualitative feedback from debrief discussions. Conclusion Implementation of a pilot preceptor bootcamp program addressing major areas of precepting skill was well received, resulted in positive feedback from operational pharmacy preceptors, and was feasible to implement at a large academic medical center.

scholarly journals 622 PD-L1 is a potential predictive biomarker for response to RM-1929 treatment in recurrent head and neck squamous cell carcinoma patients

2020 ◽  
Vol 8 (Suppl 3) ◽  
pp. A658-A658
Author(s):  
C Daniel De Magalhaes Filho ◽  
Chung-Wein Lee ◽  
Nikolai Suslov ◽  
Jerry Fong ◽  
Miguel Garcia-Guzman
Keyword(s):  
Head And Neck ◽  
Response Rate ◽  
Medical Center ◽  
Predictive Biomarker ◽  
Institutional Review Board ◽  
Cancer Center ◽  
University Of Texas ◽  
University Of Oklahoma ◽  
Institutional Review ◽  
Oklahoma Health

BackgroundRM-1929 is an antibody-dye conjugate comprised of cetuximab covalently linked to the photoactivable dye, IRDye® 700DX (IR700). After systemic infusion of RM-1929, illumination of the tumor with 690 nm non-thermal red light activates the drug and results in targeted and rapid tumor necrosis. Previous preclinical data have shown that RM-1929 treatment triggers immunogenic cell death and activates the innate and adaptive immune response. A retrospective analysis of PD-L1 expression from the phase I/IIa clinical trial in patients with recurrent head and neck squamous cell carcinoma (rHNSCC) (NCT02422979) was conducted. The analysis explored correlations of PD-L1 expression, including combined proportion score (CPS) and tumor proportion score (TPS), with clinical outcomes such as response rate and overall survival.MethodsPD-L1 expression prior to RM-1929 treatment was assessed by immunohistochemistry in 18 out of 30 patients enrolled in Part II of the trial, based on sample availability. PD-L1 expression was evaluated using TPS and CPS. Responders were defined as patients that achieved complete response or partial response, and non-responders had either stable disease or progressive disease. Overall survival (OS) was analyzed using the Kaplan-Meier method.ResultsResponders (n=10) had a TPS of 4.3±2.4 (mean±SEM), which was substantially lower than in non-responders (n=8) with a TPS of 39.4±11.8. Similarly, CPS was lower in responders (8.6±3.6) compared to non-responders (50.0±13.5). The best target response rate for all patients included in this analysis was 56%. Patients with CPS=40 had a response rate of 76.9% (n=13) compared to 0% in patients with CPS>40 (n=5). This suggests that a CPS cut-off of =40 led to enrichment of the best target response rate. The median OS of patients with CPS=40 (13.0±0.8 months) was also higher than in patients with CPS>40 (3.1±0.8 months) and in all patients (12.0±2.9 months).ConclusionsThese results suggest that rHNSCC patients with lower PD-L1 expression levels may be more responsive to RM-1929 treatment and CPS/TPS could potentially be predictive biomarkers in identifying patients with a higher probability of benefiting from this treatment. Given the limited number of patients in this analysis, additional clinical trials will be needed to validate PD-L1 expression as an effective predictive biomarker for RM-1929 treatment.AcknowledgementsThe authors would like to thank all patients and their families for their participation in this trial. The authors would also like to thank the following investigators for the contribution of samples included in this trial analysis: Dr. David Cognetti (Thomas Jefferson University Hospital), Dr. Ann M Gillenwater (University of Texas MD Anderson Cancer Center), Dr. Mary Jo Fidler (Rush University Medical Center), Dr. Samith T. Kochuparambil (Virginia Piper Cancer Institute ), Dr. John Campana (University of Colorado Head and Neck Specialists), and Dr. Nilesh R. Vasan (University of Oklahoma Health Sciences Center).Trial RegistrationNCT02422979Ethics ApprovalThe trial was approved by the following Instution Ethics Boards and IRB# as listed: UCSF Institutional Review Board (#17-21904), Thomas Jefferson University, IRB (#16C.328), University of Oklahoma Health Sciences Center Institutional Review Board (#5723), University of Texas MD Anderson Cancer Center - Institutional Review Board (#IRB 2 IRB00002203), Quorum Review IRB (#30458/1), Rush University Medical Center Institutional Review Board (#15030601-IRB01), and Catholic Health Initiatives Institute for Research and Innovation (CIRI) Institutional Review Board (CHIRB) (# IRB00009715).ConsentN/A

scholarly journals 30. Commission des Vitesses Radiales Stellaires

1936 ◽  
Vol 5 ◽  
pp. 188-196
Author(s):  
M. J. S. Plaskett ◽  
MM. Adams ◽  
Campbell ◽  
Frost ◽  
Guthnick ◽  
...  
Keyword(s):  
Radial Velocity ◽  
Pacific Coast ◽  
Radial Velocities ◽  
University Of Michigan ◽  
University Of Texas ◽  
University Of Toronto ◽  
Visual Magnitude ◽  
Under Construction ◽  
The University

The three years that have elapsed since the Harvard meeting of the Union have witnessed steady progress in the determination of radial velocities. While the three large Pacific Coast Observatories have naturally been able to make the greatest additions to radial velocity work, the Yerkes Observatory, the Simeiz Observatory and the Observatory of the University of Michigan have also made valuable contributions. It is a pleasure to report that there will soon be three major accessions to the list of observatories capable of determining radial velocities. The David Dunlap Observatory of the University of Toronto with its 74-inch telescope, which should be in operation soon after the meeting, will have radial velocities as a prominent feature of its programme. The McDonald Observatory of the University of Texas with an 80-inch telescope now under construction should be ready to commence operations in 1936 and will undertake an extensive radial velocity programme. The Radcliffe Observatory at Oxford has now been granted permission by the Courts to remove to Pretoria, South Africa, and will establish there a 74-inch reflecting telescope, which will also be largely employed in the determination of the urgently needed radial velocities of the southern stars fainter than 5.5 visual magnitude. The Commission may, I believe, congratulate itself that substantial assistance in the preliminary steps leading to this permission of removal was provided by our action at the last meeting in presenting a resolution to the Union, duly passed by the General Assembly, pointing out the urgent need for additional radial velocities in the southern sky, and strongly supporting the project of the Radcliffe Observatory to establish a large telescope at Pretoria.

scholarly journals The Twin Research Registry at SRI International

2012 ◽  
Vol 16 (1) ◽  
pp. 463-470 ◽  
Author(s):  
Ruth E. Krasnow ◽  
Lisa M. Jack ◽  
Christina N. Lessov-Schlaggar ◽  
Andrew W. Bergen ◽  
Gary E. Swan
Keyword(s):  
San Francisco ◽  
Medical Center ◽  
Second Hand Smoke ◽  
Cancer Center ◽  
Radio Stations ◽  
Twin Research ◽  
Varicella Zoster ◽  
University Of Texas ◽  
Before And After ◽  
The University

The Twin Research Registry (TRR) at SRI International is a community-based registry of twins established in 1995 by advertising in local media, mainly on radio stations and in newspapers. As of August 2012, there are 3,120 same- and opposite-sex twins enrolled; 86% are 18 years of age or older (mean age 44.9 years, SD 16.9 years) and 14% less than 18 years of age (mean age 8.9 years, SD 4.5); 67% are female, and 62% are self-reported monozygotic (MZ). More than 1,375 twins have participated in studies over the last 15 years in collaboration with the University of California Medical Center in San Francisco, the University of Texas MD Anderson Cancer Center, and the Stanford University School of Medicine. Each twin completes a registration form with basic demographic information either online at the TRR Web site or during a telephone interview. Contact is maintained with members by means of annual newsletters and birthday cards. The managers of the TRR protect the confidentiality of twin data with established policies; no information is given to other researchers without prior permission from the twins; and all methods and procedures are reviewed by an Institutional Review Board. Phenotypes studied thus far include those related to nicotine metabolism, mutagen sensitivity, pain response before and after administration of an opioid, and a variety of immunological responses to environmental exposures, including second-hand smoke and vaccination for seasonal influenza virus and Varicella zoster virus. Twins in the TRR have participated in studies of complex, clinically relevant phenotypes that would not be feasible to measure in larger samples.

The history of neurosurgery at Baylor College of Medicine

2021 ◽  
pp. 1-11
Author(s):  
Visish M. Srinivasan ◽  
Caroline C. Hadley ◽  
Akash J. Patel ◽  
Bruce L. Ehni ◽  
Howard L. Weiner ◽  
...  
Keyword(s):  
Residency Program ◽  
Medical Center ◽  
Cancer Center ◽  
Baylor College ◽  
Texas Medical ◽  
University Of Texas ◽  
History Of Neurosurgery ◽  
History Of ◽  
Md Anderson ◽  
The University

The development of neurosurgery at Baylor College of Medicine began with the medical school’s relocation to the new Texas Medical Center in Houston in 1943. An academic service was organized in 1949 as a section of neurosurgery within Baylor’s Department of Surgery. Soon the practice, led by Dr. George Ehni, evolved to include clinical services at Methodist, Jefferson Davis (forerunner of Ben Taub), Texas Children’s, the Veterans Affairs, and the University of Texas MD Anderson Cancer Center hospitals. A neurosurgery residency program was established in 1954. As the clinical practice expanded, neurosurgery was upgraded from a section to a division and then to a department. It has been led by four chiefs/chairs over the past 60 years—Dr. George Ehni (1959–1979), Dr. Robert Grossman (1980–2004), Dr. Raymond Sawaya (2005–2014), and Dr. Daniel Yoshor (2015–2020). Since the 1950s, the department has drawn strength from its robust residency program, its research base in the medical school, and its five major hospital affiliates, which have largely remained unchanged (with the exception of Baylor St. Luke’s Medical Center replacing Methodist in 2004). The recent expansion of the residency program to 25 accredited positions and the growing strength of relationships with the “Baylor five” hospitals affiliated with Baylor College of Medicine portend a bright future.

Commentary on: “Satisfaction with information used to choose prostate cancer treatment.” Gilbert SM, Sanda MG, Dunn RL, Greenfield TK, Hembroff L, Klein E, Saigal CS, Pisters L, Michalski J, Sandler HM, Litwin MS, Wei JT. H. Lee Moffitt Cancer Center, Tampa, Florida; Department of Urology, Emory University, Atlanta, Georgia; Department of Urology, University of Michigan, Ann Arbor, Michigan; Department of Psychiatry and Public Health Institute, University of California-San Francisco, California; Institute for Public Policy and Social Research, Michigan State University, Lansing, Michigan; Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio; Department of Urology and Department of Health Policy and Management, University of California-Los Angeles, Los Angeles, California; Department of Urology, University of Texas M.D. Anderson Cancer Center, Houston, Texas; Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri; Department of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, California.

2016 ◽  
Vol 34 (5) ◽  
pp. 247-248
Author(s):  
Hollenbeck Brent
Keyword(s):  
Los Angeles ◽  
San Francisco ◽  
Radiation Oncology ◽  
Social Research ◽  
Medical Center ◽  
Cleveland Clinic ◽  
University Of California ◽  
Cancer Center ◽  
California Department ◽  
University Of Texas

Evaluating the Validity of a Bayesian Program for Predicting Stage in Hodgkin’s Disease

1981 ◽  
Vol 20 (03) ◽  
pp. 174-178 ◽  
Author(s):  
A. I. Barnett ◽  
J. Cynthia ◽  
F. Jane ◽  
Nancy Gutensohn ◽  
B. Davies
Keyword(s):  
New England ◽  
Hodgkin's Disease ◽  
Bayesian Model ◽  
Medical Center ◽  
Hodgkin’S Disease ◽  
Test Procedure ◽  
Disease Patient ◽  
Probabilistic Information ◽  
Probabilistic Forecasts ◽  
England Medical

A Bayesian model that provides probabilistic information about the spread of malignancy in a Hodgkin’s disease patient has been developed at the Tufts New England Medical Center. In assessing the model’s reliability, it seemed important to use it to make predictions about patients other than those relevant to its construction. The accuracy of these predictions could then be tested statistically. This paper describes such a test, based on 243 Hodgkin’s disease patients of known pathologic stage. The results obtained were supportive of the model, and the test procedure might interest those wishing to determine whether the imperfections that attend any attempt to make probabilistic forecasts have gravely damaged their accuracy.

Sign in / Sign up

Export Citation Format

Share Document